S. 2338 — Introduced in Senate

II 113th CONGRESS 2d Session S. 2338 IN THE SENATE OF THE UNITED STATES May 14, 2014Mr. Rockefeller (for himself and Mr. Thune) introduced the following bill; which was read twice and referred to the Committee on Commerce, Science, and Transportation A BILL To reauthorize the United States Anti-Doping Agency, and for other purposes. 1. Short title This Act may be cited as the United States Anti-Doping Agency Reauthorization Act. 2. Prohibit performance-enhancing methods Section 701 of title VII of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is amended— (1) in subsection (a), by striking paragraph (4); and (2) in subsection (b)— (A) in paragraph (1), by inserting and be recognized worldwide as the independent national anti-doping organization for the United States after Committee; (B) in paragraph (2), by striking , or performance-enhancing genetic modifications accomplished through gene-doping and inserting or prohibited performance-enhancing methods adopted by the Agency; (C) in paragraph (3), by striking , or performance-enhancing genetic modifications accomplished through gene-doping and inserting or prohibited performance-enhancing methods adopted by the Agency; (D) in paragraph (4), by striking and the prevention of use of performance-enhancing drugs, or performance-enhancing genetic modifications accomplished through gene-doping by United States amateur athletes; and and inserting , and the prevention of use by United States amateur athletes of performance-enhancing drugs or prohibited performance-enhancing methods adopted by the Agency.; and (E) by striking paragraph (5). 3. Authorization of appropriations Section 703 of title VII of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2003) is amended to read as follows: 703. Authorization of appropriations There are authorized to be appropriated to the United States Anti-Doping Agency— (1) for fiscal year 2014, $11,300,000; (2) for fiscal year 2015, $11,700,000; (3) for fiscal year 2016, $12,300,000; (4) for fiscal year 2017, $12,900,000; (5) for fiscal year 2018, $13,500,000; (6) for fiscal year 2019, $14,100,000; and (7) for fiscal year 2020, $14,800,000. .